Get started
Author

Daniel Fallon

Observed names: Dan Fallon, Daniel H. Fallon
ORCID: 0009-0001-5367-8873
Observed ORCID: 0009-0001-5367-8873
OpenAlex ID: A5093988192
Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET® CC-96191
2024 · Margaret C. Lunn-Halbert, George S. Laszlo, et al. · Cancers · 9
PDF
Agonistic anti-NKG2D antibody structure reveals unique stoichiometry and epitope compared to natural ligands
2024 · Daniel Fallon, Ching-Shin Huang, et al. · mAbs · 2
PDF
DF6215, an α-optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activity
2025 · Adam P. Stockmann, Sylvia Vincent, et al. · Cell Reports Medicine · 1
Abstract P4-08-23: Preclinical characterization of DF1001, a first-in-class dual NK and T cell engager targeting HER2-high or HER2-low tumors
2025 · Laurens Lambert, Gregory Chang, et al. · Clinical Cancer Research · 1
Discovery and characterization of an agonistic anti-NKG2D antibody
2025 · Daniel H. Fallon · Digital Repository Service (Northeastern University)
962 A novel alpha-active IL-2-Fc has expanded therapeutic index and robust monotherapy efficacy in mouse cancer models and strong synergy with PD-1 blockade
2024 · Adam P Stockmann, Sylvia Vincent, et al. · Journal for ImmunoTherapy of Cancer
Works count: 6
Citation count: 13
H-index: 2
I10-index:
Year
Topic
Type